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CASE  REPORT
ABSTRACT
Sunitinib (Sutent: Pfizer, New York, NY, U.S.A.) is an
oral multi-targeted tyrosine kinase inhibitor approved
for use in various solid tumour malignancies. Many
side effects secondary to sunitinib have been docu-
mented. In particular, sunitinib administration is known
to result in thrombocytopenia, with the cause being at-
tributed to myelosuppression. Here, we present the first
case report to demonstrate immune-mediated throm-
bocytopenia secondary to sunitinib administration.
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1. INTRODUCTION
Sunitinib (Sutent: Pfizer, New York, NY, U.S.A.) is an
oral multi-targeted tyrosine kinase inhibitor, for which
a role is being established as first- or second-line treat-
ment in various malignancies. Sunitinib acts as an in-
hibitor of the vascular endothelial growth factor
receptors 1, 2, and 3, and platelet-derived growth fac-
tor receptors a and b. It inhibits various tyrosine kinases
such as stem-cell factor receptor Kit, colony stimulat-
ing factor 1, fetal liver tyrosine kinase receptor 3, and
the glial cell line–derived neurotrophic factor receptor.
In doing so, sunitinib has demonstrated reductions in
tumour cell proliferation, increased apoptosis, reduced
tissue invasion, and reduced angiogenesis 1,2.
To date, clinically approved uses for sunitinib in-
clude first-line treatment of metastatic renal-cell car-
cinoma and second-line treatment of gastrointestinal
stromal tumours resistant to imatinib mesylate
(Gleevec: Novartis Pharmaceuticals, St. Louis, MO,
U.S.A.). However, sunitinib is in widespread use in
clinical trials for both hematologic and solid-tumour
malignancies. Toxicities reported with sunitinib use
include hypertension, fatigue, skin toxicity (that is,
hand–foot syndrome), diarrhea, vomiting, neutropenia,
and thrombocytopenia 3,4. Here, we present the first
reported case of drug-induced immune thrombocyto-
penic purpura secondary to sunitinib in a woman treated
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2. PRESENTATION
A 52-year-old woman with recently diagnosed hormone
receptor–positive and human epidermal growth factor
receptor 2–positive metastatic breast cancer was enrolled
in a phase II clinical trial in which she received sunitinib
50 mg daily and trastuzumab (Herceptin: Genentech,
San Francisco, CA, U.S.A.) 8 mg/kg loading, and then
6 mg/kg every 3 weeks, as first-line treatment. The
patient’s prior medical history was unremarkable for
any autoimmune or hepatic disorders, HIV, or bleeding
diatheses. She was a non-smoker and did not consume
alcohol. Baseline complete blood count revealed
hemoglobin 140 g/L, white blood cell count 9.4×109/L,
and platelet count 269×109/L. Two weeks after starting
the clinical trial, the patient was started on omeprazole
for dyspepsia. She was not prescribed any other medi-
cations, and she did not subscribe to any non-conven-
tional therapy.
Following 3 weeks of sunitinib treatment, the
patient experienced a fall off a bicycle and noted ex-
cessive bruising over the areas of impact on her up-
per and lower extremities. She subsequently developed
recurrent epistaxis refractory to conventional treat-
ment measures, prompting her presentation to a com-
munity emergency department. At that time, the
patient’s platelet count was 1×109/L. Her bleeding sta-
bilized after nasal packing and 5 units of transfused
platelets.
2.1 Investigations
A complete blood count performed on the day fol-
lowing the platelet transfusion revealed hemoglobin
123 g/L, white blood cell count 4.0×109/L, and plate-
let count 1×109/L, suggesting a refractory response to
platelet transfusion. Peripheral blood film reflected
thrombocytopenia, with no evidence of schistocyto-
sis, spherocytosis, or dysplasia. Baseline mean plate-
let volume had increased from 7.7 fL to 18 fL (normal
range: 5–15 fL).
Other laboratory investigations yielded normal
renal and liver function tests, a normal coagulation
screen (international normalized ratio, prothrombin
time, partial thromboplastin time), and a normalTRINKAUS et al.
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electrolyte profile. Physical examination was remark-
able for oropharyngeal petechiae and diffuse ecchy-
moses, petechiae, and some purpuric lesions on the
extremities. No splenomegaly was present.
The patient was admitted to hospital with a diag-
nosis of refractory thrombocytopenia. Notably, the last
dose of trastuzumab had been administered the week
before this patient’s documented thrombocytopenia, and
sunitinib had been taken the day before.
2.2 Course of Treatment
Preliminary diagnosis was drug-induced immune
thrombocytopenic purpura. The patient was treated with
intravenous immunoglobulin (IVIG) at 70 g (1 g/kg) over
2 days, and she also received tranexamic acid. Her
platelet count rapidly improved to 101×109/L (7 days
after the IVIG treatment) and returned to her normal
baseline of 236×109/L after 2 weeks.
Repeat imaging within 3 weeks of this patient’s
last treatment with sunitinib and trastuzumab revealed
growth of her visceral metastases. Trastuzumab was
reintroduced at a lower weekly dose (2 mg/kg) with no
drop in platelet count.
Normalization of this patient’s platelet count post
IVIG and post withholding of sunitinib is fully consist-
ent with immune-induced thrombocytopenia second-
ary to sunitinib. She was thereafter started on alternative
systemic treatment with good response and stability in
her platelet count.
3. DISCUSSION
Immune-mediated thrombocytopenia is associated with
various autoimmune disorders, HIV, hematologic ma-
lignancies, chronic infections, and medications. Drug-
induced immune thrombocytopenia is thought to be a
result of antibody production in the presence of a sen-
sitizing medication, with the antibodies targeting
epitopes on the platelet surface, subsequently leading
to clearance of the antibody-coated platelets by the
mononuclear phagocytic system 5.
Bleeding occurs in autoimmune thrombocytope-
nia not because antibody-coated platelets are dysfunc-
tional, but rather because platelet numbers decline to
at least 50×109/L or lower 6. Drug-induced immune
thrombocytopenia usually results in a drop in platelet
count within 5–7 days of first medication exposure 5.
Unlike primary or idiopathic thrombocytopenic pur-
pura, drug-induced autoimmune thrombocytopenia
usually resolves following withdrawal of the offend-
ing agent.
Autoimmune thrombocytopenia at time of diagno-
sis or during the course of breast cancer has been docu-
mented in case reports, suggesting the rarity of this
phenomenon 7,8. The small number of cases of im-
mune thrombocytopenia in conjunction with breast
cancer adds to the difficulty of determining an actual
pathophysiologic link between the two conditions. One
small series of 10 breast cancer patients with immune
thrombocytopenia suggested a mechanism of tumour-
induced immunologic thrombocytopenia 8.
Sunitinib has been documented to result in throm-
bocytopenia, with the causation attributed mainly to
myelosuppression. In a phase I dose-escalation trial
involving various types of cancer, sunitinib at 50 mg
daily caused thrombocytopenia in 2 of 9 patients 5.
In a phase III trial of metastatic renal cell cancer
patients, Motzer et al. 3 reported some grade of throm-
bocytopenia in 65 of 375 patients randomized to
sunitinib treatment, with 8 of the 65 (12%) having grade
3 thrombocytopenia.
One case of sunitinib-induced malignant hyperten-
sion causing thrombocytopenia secondary to micro-
angiopathy has been reported 9.
Ours is the first documented case of a temporal
association of sunitinib administration with a resultant
immune-related thrombocytopenia. The possibility of
an immunologic phenomenon to account for sunitinib-
induced immune thrombocytopenia is reasonable, given
its association with exacerbation of other autoimmune
disorders such as hypothyroidism 10. The exact mecha-
nism by which sunitinib induced an immune-mediated
thrombocytopenia is unknown.
4. CONCLUSIONS
Our case raises the possibility that the new multi-tar-
geted tyrosine kinase inhibitors such as sunitinib may
have multiple side effects that have not yet been fully
elucidated. In the context of thrombocytopenia follow-
ing initiation of sunitinib, clinicians need to have a high
index of suspicion for the potential of immune-medi-
ated thrombocytopenia. In this regard, the medication
can safely be discontinued.
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